<DOC>
	<DOCNO>NCT00003192</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness aminocamptothecin treat patient locally advance , metastatic , recurrent cancer stomach esophagus .</brief_summary>
	<brief_title>Aminocamptothecin Treating Patients With Stomach Cancer Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate 120 hour continuous infusion aminocamptothecin ( 9-AC ) chemotherapy naive patient adenocarcinoma stomach gastroesophageal junction . II . Characterize nature toxicity 9-AC schedule patient population . III . Determine duration response , time progression , survival patient population . IV . Study pharmacokinetics pharmacodynamics 9-AC schedule patient . OUTLINE : This open label , multicenter study . Patients receive intravenous aminocamptothecin continuous infusion 120 hour day 1-5 8-12 follow 1 week rest 3 week cycle . Therapy continue minimum 6 week ( 2 full cycle ) unless unacceptable toxic effect rapid disease progression . Dose escalation may occur patient complete 3 cycle therapy without unacceptable toxicity . All patient follow survival . PROJECTED ACCRUAL : This study accrue 14-40 patient within 18 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>9-aminocamptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , locally advanced , metastatic recurrent adenocarcinoma stomach gastroesophageal junction Measurable disease CNS metastases allow provided patient sit measurable disease , neurologically stable , receive concurrent anticonvulsant therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : CALGB 02 Life expectancy : Not specify Hematopoietic : WBC least 3500/mm3 Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 ( platelet transfusion within 7 day ) Hemoglobin least 9 g/dL Hepatic : Total bilirubin great 1.5 mg/dL Transaminases great 2.5 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis ) Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent uncontrolled medical psychiatric condition No active uncontrolled infection No prior malignant disease within past 5 year except curatively treat nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent prophylactic growth factor Chemotherapy : One prior adjuvant neoadjuvant 5FUbased chemotherapy regimen allow At least 4 week since prior adjuvant neoadjuvant chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior therapy topoisomerase I inhibitor No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : One prior radiotherapy regimen allow No prior radiation therapy site measurable disease At least 4 week since prior radiation therapy recover No concurrent palliative radiation therapy Surgery : Not specify Other : See Disease Characteristics No concurrent investigational antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>